Art

J-GLOBAL ID：202002289535564752   Reference number：20A0624957

呼吸器病学TOPICS 2019-20 5.びまん性肺疾患 SENSCIS trialからみた強皮症に伴う間質性肺疾患に対する抗線維化療法

Author (1)： KUWANA MASATAKA (日本医大 大学院医学研究科 アレルギー膠原病内科学分野)
Material： 分子呼吸器病  (Respiratory Molecular Medicine)
Volume： 24  Issue： 1  Page： 32-35  Publication year： Mar. 01, 2020 
JST Material Number： L3361A  ISSN： 1342-436X  CODEN： BUKOFC  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *scleroderma ,...
Semi thesaurus term： Lung Diseases, Interstitial ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0624957&from=J-GLOBAL&jstjournalNo=L3361A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for respiratory system diseases  (GI05020J) ,  Clinical application of drugs acting on respiration and respiratory system  (GW08020U)

Substance index (3)： Cyclophosphamid ,  Nintedanib ,  Mofetil mycophenolate

Reference (17)：

• Tyndal AJ et al : Causes and risk factors for death in systemic sclerosis : a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 : 1809-1815, 2010
• Distler O et al : Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380 :2518-2528, 2019
• Man A et al :Changes in forced vital capacity over time in systemic sclerosis : application of group-based trajectory modeling. Rheumatology 54 : 1464-1471, 2015
• Kuwana M et al :Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 43: 1825-1831, 2016
• Tashkin DP et al :Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354: 2655-2666, 2006

Terms in the title (6)： 呼吸器病学 ,  びまん性肺疾患 ,  強皮症 ,  間質性肺疾患 ,  線維化 ,  療法